{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:33:01Z","timestamp":1792092781875,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"DOI":"10.1007\/s10555-026-10365-8","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:47:54Z","timestamp":1785822474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunological and antitumor responses to HPV-targeted therapeutic vaccines in preclinical models of head and neck cancer: a systematic review"],"prefix":"10.1007","volume":"45","author":[{"given":"Sara","family":"Fraser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darya","family":"Tamashekan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mascarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Florianova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire B.","family":"Morand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex M.","family":"Mlynarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Hier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina D. S.","family":"Wurzba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"10365_CR1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41416-019-0602-7","volume":"122","author":"ME Sabatini","year":"2020","unstructured":"Sabatini, M. E., & Chiocca, S. (2020). Human papillomavirus as a driver of head and neck cancers. British Journal of Cancer, 122, 306\u2013314. https:\/\/doi.org\/10.1038\/s41416-019-0602-7","journal-title":"British Journal of Cancer"},{"key":"10365_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215406","author":"LRC Castellano","year":"2022","unstructured":"Castellano, L. R. C., et al. (2022). Implications and emerging therapeutic avenues of inflammatory response in HPV+ head and neck squamous cell carcinoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14215406","journal-title":"Cancers (Basel)"},{"key":"10365_CR3","doi-asserted-by":"publisher","unstructured":"Leemans, C. R., Snijders, P. J. F. & Brakenhoff, R. H. The molecular landscape of head and neck cancer. Nature Reviews Cancer 18, 269\u2013282 (2018).https:\/\/doi.org\/10.1038\/nrc.2018.11","DOI":"10.1038\/nrc.2018.11"},{"key":"10365_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2982","volume":"11","author":"CR Leemans","year":"2011","unstructured":"Leemans, C. R., Braakhuis, B. J. M., & Brakenhoff, R. H. (2011). The molecular biology of head and neck cancer. Nature Reviews Cancer, 11, 9\u201322. https:\/\/doi.org\/10.1038\/nrc2982","journal-title":"Nature Reviews Cancer"},{"key":"10365_CR5","doi-asserted-by":"publisher","unstructured":"Morand, G. B. et al. Therapeutic vaccines for HPV-associated oropharyngeal and cervical cancer: The next de-intensification strategy? Int J Mol Sci 23 (2022). https:\/\/doi.org\/10.3390\/ijms23158395","DOI":"10.3390\/ijms23158395"},{"key":"10365_CR6","doi-asserted-by":"publisher","unstructured":"Yan, F., Cowell, L. G., Tomkies, A. & Day, A. T. Therapeutic vaccination for HPV-mediated cancers. Current Otorhinolaryngology Reports 11, 44\u201361 (2023).https:\/\/doi.org\/10.1007\/s40136-023-00443-8","DOI":"10.1007\/s40136-023-00443-8"},{"key":"10365_CR7","doi-asserted-by":"publisher","unstructured":"Bouassaly, J. et al. Rethinking treatment paradigms: Neoadjuvant therapy and de-escalation strategies in HPV-positive head and neck cancer. Crit Rev Oncol Hematol 196, 104326 (2024). https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104326","DOI":"10.1016\/j.critrevonc.2024.104326"},{"key":"10365_CR8","doi-asserted-by":"publisher","unstructured":"Brook, I. Late side effects of radiation treatment for head and neck cancer. Radiation Oncology Journal 38, 84\u201392 (2020).https:\/\/doi.org\/10.3857\/roj.2020.00213","DOI":"10.3857\/roj.2020.00213"},{"key":"10365_CR9","doi-asserted-by":"publisher","unstructured":"Sadeghi, N. et al. Pathologic response to neoadjuvant chemotherapy in HPV-associated oropharynx cancer. Head Neck 42, 417\u2013425 (2020).https:\/\/doi.org\/10.1002\/hed.26022","DOI":"10.1002\/hed.26022"},{"key":"10365_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.coms.2018.09.002","volume":"31","author":"F Sim","year":"2019","unstructured":"Sim, F., Leidner, R., & Bell, R. B. (2019). Immunotherapy for head and neck cancer. Oral and Maxillofacial Surgery Clinics of North America, 31, 85\u2013100. https:\/\/doi.org\/10.1016\/j.coms.2018.09.002","journal-title":"Oral and Maxillofacial Surgery Clinics of North America"},{"key":"10365_CR11","doi-asserted-by":"publisher","unstructured":"Dogan, V., Rieckmann, T., M\u00fcnscher, A. & Busch, C.-J. Current studies of immunotherapy in head and neck cancer. Clinical Otolaryngology 43, 13\u201321 (2018).https:\/\/doi.org\/10.1111\/coa.12895","DOI":"10.1111\/coa.12895"},{"key":"10365_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236041","volume":"13","author":"S Beyaert","year":"2021","unstructured":"Beyaert, S., Machiels, J.-P., & Schmitz, S. (2021). Vaccine-based immunotherapy for head and neck cancers. Cancers, 13, Article 6041.","journal-title":"Cancers"},{"key":"10365_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/v14122824","volume":"14","author":"Q Xu","year":"2022","unstructured":"Xu, Q., et al. (2022). Advanced nanomedicine for high-risk HPV-driven head and neck cancer. Viruses, 14, Article 2824.","journal-title":"Viruses"},{"key":"10365_CR14","doi-asserted-by":"publisher","unstructured":"Devaraja, K., Aggarwal, S. & Singh, M. Therapeutic vaccination in head and neck squamous cell carcinoma-A review. Vaccines 11, 634 (2023).https:\/\/doi.org\/10.3390\/vaccines11030634","DOI":"10.3390\/vaccines11030634"},{"key":"10365_CR15","doi-asserted-by":"publisher","unstructured":"Meliante, P. G., Petrella, C., Fiore, M., Minni, A. & Barbato, C. Head and neck squamous cell carcinoma vaccine: Current landscape and perspectives. Curr Issues Mol Biol 45, 9215\u20139233 (2023).\u00a0https:\/\/doi.org\/10.3390\/cimb45110577","DOI":"10.3390\/cimb45110577"},{"key":"10365_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010033","volume":"14","author":"JZ Zhou","year":"2022","unstructured":"Zhou, J. Z., Jou, J., & Cohen, E. (2022). Vaccine strategies for human papillomavirus-associated head and neck cancers. Cancers, 14, Article 33. https:\/\/doi.org\/10.3390\/cancers14010033","journal-title":"Cancers"},{"key":"10365_CR17","doi-asserted-by":"publisher","unstructured":"Smalley Rumfield, C., Roller, N., Pellom, S. T., Schlom, J. & Jochems, C. Therapeutic vaccines for HPV-associated malignancies. ImmunoTargets and therapy9, 167\u2013200 (2020).https:\/\/doi.org\/10.2147\/ITT.S273327","DOI":"10.2147\/ITT.S273327"},{"key":"10365_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans, C. R., et al. (2014). SYRCLE\u2019s risk of bias tool for animal studies. BMC Medical Research Methodology, 14, Article 43. https:\/\/doi.org\/10.1186\/1471-2288-14-43","journal-title":"BMC Medical Research Methodology"},{"key":"10365_CR19","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1002\/lary.26737","volume":"127","author":"J Ahn","year":"2017","unstructured":"Ahn, J., et al. (2017). Immunologic responses to a novel DNA vaccine targeting human papillomavirus-11 E6E7. The Laryngoscope, 127, 2713\u20132720. https:\/\/doi.org\/10.1002\/lary.26737","journal-title":"The Laryngoscope"},{"key":"10365_CR20","doi-asserted-by":"publisher","unstructured":"Bartkowiak, T. et al. Unique potential of 4\u20131BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6\/E7 peptide vaccine. Proceedings of the National Academy of Sciences 112, E5290-E5299 (2015). https:\/\/doi.org\/10.1073\/pnas.1514418112","DOI":"10.1073\/pnas.1514418112"},{"key":"10365_CR21","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1016\/j.vaccine.2019.04.043","volume":"37","author":"DM Da Silva","year":"2019","unstructured":"Da Silva, D. M., et al. (2019). Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease. Vaccine, 37, 2915\u20132924. https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.043","journal-title":"Vaccine"},{"key":"10365_CR22","doi-asserted-by":"publisher","unstructured":"Dorta-Estremera, S. et al. Mucosal HPV E6\/E7 peptide vaccination in combination with immune checkpoint modulation induces regression of HPV+ oral cancers. Cancer Research 78, 5327\u20135339 (2018). https:\/\/doi.org\/10.1158\/0008-5472.Can-18-0892","DOI":"10.1158\/0008-5472.Can-18-0892"},{"key":"10365_CR23","doi-asserted-by":"publisher","unstructured":"Ishida, E. et al. Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model. Cancer Immunology, Immunotherapy 68, 1273\u20131286 (2019).https:\/\/doi.org\/10.1007\/s00262-019-02357-1","DOI":"10.1007\/s00262-019-02357-1"},{"key":"10365_CR24","doi-asserted-by":"publisher","unstructured":"Lin, Y.-H. et al. Integration of oncogenes via sleeping beauty as a mouse model of HPV16+ oral tumors and immunologic control. Cancer Immunology Research 6, 305\u2013319 (2018).https:\/\/doi.org\/10.1158\/2326-6066.Cir-16-0358","DOI":"10.1158\/2326-6066.Cir-16-0358"},{"key":"10365_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12020206","volume":"12","author":"MP O\u2019Hara","year":"2024","unstructured":"O\u2019Hara, M. P., Yanamandra, A. V., & Sastry, K. J. (2024). Immunity from NK cell subsets is important for vaccine-mediated protection in HPV+ cancers. Vaccines, 12, Article 206.","journal-title":"Vaccines"},{"key":"10365_CR26","doi-asserted-by":"publisher","unstructured":"Smalley Rumfield, C., Pellom, S. T., Morillon Ii, Y. M., Schlom, J. & Jochems, C. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine. J Immunother Cancer 8 (2020).https:\/\/doi.org\/10.1136\/jitc-2020-000612","DOI":"10.1136\/jitc-2020-000612"},{"key":"10365_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-021-00759-x","volume":"28","author":"S-H Tseng","year":"2021","unstructured":"Tseng, S.-H., et al. (2021). Control of spontaneous HPV16 E6\/E7 expressing oral cancer in HLA-A2 (AAD) transgenic mice with therapeutic HPV DNA vaccine. Journal of Biomedical Science, 28, 1\u201312. https:\/\/doi.org\/10.1186\/s12929-021-00759-x","journal-title":"Journal of Biomedical Science"},{"key":"10365_CR28","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/2326-6066.Cir-16-0128","volume":"4","author":"W Yin","year":"2016","unstructured":"Yin, W., et al. (2016). Therapeutic HPV cancer vaccine targeted to CD40 elicits effective CD8+ T-cell immunity. Cancer Immunology Research, 4, 823\u2013834. https:\/\/doi.org\/10.1158\/2326-6066.Cir-16-0128","journal-title":"Cancer Immunology Research"},{"key":"10365_CR29","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202317723","author":"L Douguet","year":"2023","unstructured":"Douguet, L., et al. (2023). Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine. EMBO Molecular Medicine. https:\/\/doi.org\/10.15252\/emmm.202317723","journal-title":"EMBO Molecular Medicine"},{"key":"10365_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001948","author":"S Karaki","year":"2021","unstructured":"Karaki, S., et al. (2021). CXCR6 deficiency impairs cancer vaccine efficacy and CD8+ resident memory T-cell recruitment in head and neck and lung tumors. Journal for Immunotherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-001948","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10365_CR31","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1158\/1535-7163.Mct-14-1015","volume":"14","author":"M Mondini","year":"2015","unstructured":"Mondini, M., et al. (2015). Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-associated head and neck cancer. Molecular Cancer Therapeutics, 14, 1336\u20131345. https:\/\/doi.org\/10.1158\/1535-7163.Mct-14-1015","journal-title":"Molecular Cancer Therapeutics"},{"key":"10365_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00733-8","volume":"8","author":"K Qiu","year":"2023","unstructured":"Qiu, K., et al. (2023). mRNA-LNP vaccination-based immunotherapy augments CD8+ T cell responses against HPV-positive oropharyngeal cancer. NPJ Vaccines, 8, Article 144. https:\/\/doi.org\/10.1038\/s41541-023-00733-8","journal-title":"NPJ Vaccines"},{"key":"10365_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138722","author":"C Jindra","year":"2015","unstructured":"Jindra, C., et al. (2015). Attenuated recombinant influenza A virus expressing HPV16 E6 and E7 as a novel therapeutic vaccine approach. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0138722","journal-title":"PLoS ONE"},{"key":"10365_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2023.168096","volume":"435","author":"L Riepler","year":"2023","unstructured":"Riepler, L., et al. (2023). Therapeutic efficacy of a VSV-GP-based human papilloma virus vaccine in a murine cancer model. Journal of Molecular Biology, 435, Article 168096. https:\/\/doi.org\/10.1016\/j.jmb.2023.168096","journal-title":"Journal of Molecular Biology"},{"key":"10365_CR35","doi-asserted-by":"publisher","unstructured":"Pagni, R. L. et al. Interleukin-6 and indoleamine-2,3-dioxygenase as potential adjuvant targets for Papillomavirus-related tumors immunotherapy. Frontiers in Immunology Volume 13 - 2022 (2022).https:\/\/doi.org\/10.3389\/fimmu.2022.1005937","DOI":"10.3389\/fimmu.2022.1005937"},{"key":"10365_CR36","doi-asserted-by":"publisher","first-page":"49737","DOI":"10.1021\/acsami.1c15361","volume":"13","author":"Y Song","year":"2021","unstructured":"Song, Y., et al. (2021). Precisely shaped self-adjuvanting peptide vaccines with enhanced immune responses for HPV-associated cancer therapy. ACS Applied Materials & Interfaces, 13, 49737\u201349753. https:\/\/doi.org\/10.1021\/acsami.1c15361","journal-title":"ACS Applied Materials & Interfaces"},{"key":"10365_CR37","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1007\/s10529-021-03166-2","volume":"43","author":"T Mousavi","year":"2021","unstructured":"Mousavi, T., Valadan, R., Rafiei, A., Abbasi, A., & Haghshenas, M. R. (2021). A novel recombinant protein vaccine containing the different E7 proteins of the HPV16, 18, 6, 11 E7 linked to the HIV-1 Tat (47\u201357) improve cytotoxic immune responses. Biotechnology Letters, 43, 1933\u20131944. https:\/\/doi.org\/10.1007\/s10529-021-03166-2","journal-title":"Biotechnology Letters"},{"key":"10365_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121542","volume":"286","author":"S Puth","year":"2022","unstructured":"Puth, S., et al. (2022). An all-in-one adjuvanted therapeutic cancer vaccine targeting dendritic cell cytosol induces long-lived tumor suppression through NLRC4 inflammasome activation. Biomaterials, 286, Article 121542. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121542","journal-title":"Biomaterials"},{"key":"10365_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1912473","volume":"10","author":"S Domingos-Pereira","year":"2021","unstructured":"Domingos-Pereira, S., et al. (2021). Vaccination with a nanoparticle E7 vaccine can prevent tumor recurrence following surgery in a human papillomavirus head and neck cancer model. OncoImmunology, 10, Article 1912473. https:\/\/doi.org\/10.1080\/2162402X.2021.1912473","journal-title":"OncoImmunology"},{"key":"10365_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109439","author":"R Josi","year":"2024","unstructured":"Josi, R., et al. (2024). A tetravalent nanovaccine that inhibits growth of HPV-associated head and neck carcinoma via dendritic and T cell activation. iScience. https:\/\/doi.org\/10.1016\/j.isci.2024.109439","journal-title":"iScience"},{"key":"10365_CR41","doi-asserted-by":"publisher","unstructured":"Fahey, L. M., Raff, A. B., Da Silva, D. M., Kast, W. M. (2009). A major role for the minor capsid protein of human papillomavirus type 16 in immune escape.\u00a0The Journal of Immunology, 183(10):6151\u20136156. https:\/\/doi.org\/10.4049\/jimmunol.0902145","DOI":"10.4049\/jimmunol.0902145"},{"key":"10365_CR42","doi-asserted-by":"publisher","unstructured":"Zottnick, S., Vo\u00df, A. L. & Riemer, A. B. Inducing immunity where it matters: Orthotopic HPV tumor models and therapeutic vaccinations. Frontiers in ImmunologyVolume 11 - 2020 (2020).https:\/\/doi.org\/10.3389\/fimmu.2020.01750","DOI":"10.3389\/fimmu.2020.01750"},{"key":"10365_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s10989-021-10334-5","volume":"28","author":"Z Sun","year":"2021","unstructured":"Sun, Z., Sun, X., Chen, Z., Du, J., & Wu, Y. (2021). Head and neck squamous cell carcinoma: Risk factors, molecular alterations, immunology and peptide vaccines. International Journal of Peptide Research and Therapeutics, 28, Article 19. https:\/\/doi.org\/10.1007\/s10989-021-10334-5","journal-title":"International Journal of Peptide Research and Therapeutics"},{"key":"10365_CR44","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-020-2931-3","volume":"597","author":"A Wieland","year":"2021","unstructured":"Wieland, A., et al. (2021). Defining HPV-specific B cell responses in patients with head and neck cancer. Nature, 597, 274\u2013278. https:\/\/doi.org\/10.1038\/s41586-020-2931-3","journal-title":"Nature"},{"key":"10365_CR45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41586-021-03862-z","volume":"597","author":"CS Eberhardt","year":"2021","unstructured":"Eberhardt, C. S., et al. (2021). Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer. Nature, 597, 279\u2013284. https:\/\/doi.org\/10.1038\/s41586-021-03862-z","journal-title":"Nature"},{"key":"10365_CR46","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han, Y., Liu, D., & Li, L. (2020). PD-1\/PD-L1 pathway: Current researches in cancer. American Journal of Cancer Research, 10, 727\u2013742.","journal-title":"American Journal of Cancer Research"},{"key":"10365_CR47","doi-asserted-by":"publisher","unstructured":"Grosso, J. F. & Jure-Kunkel, M. N. CTLA-4 blockade in tumor models: An overview of preclinical and translational research. Cancer Immun 13, 5 (2013).https:\/\/doi.org\/10.1158\/1424-9634.DCL-5.13.1","DOI":"10.1158\/1424-9634.DCL-5.13.1"},{"key":"10365_CR48","doi-asserted-by":"publisher","first-page":"ii25","DOI":"10.1136\/ard.61.suppl_2.ii25","volume":"61","author":"W van Eden","year":"2002","unstructured":"van Eden, W., et al. (2002). Balancing the immune system: Th1 and Th2. Annals of the Rheumatic Diseases, 61, ii25\u2013ii28. https:\/\/doi.org\/10.1136\/ard.61.suppl_2.ii25","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10365_CR49","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1080\/14760584.2024.2374287","volume":"23","author":"A Demidova","year":"2024","unstructured":"Demidova, A., et al. (2024). Comparison of preclinical efficacy of immunotherapies against HPV-induced cancers. Expert Review of Vaccines, 23, 674\u2013687. https:\/\/doi.org\/10.1080\/14760584.2024.2374287","journal-title":"Expert Review of Vaccines"},{"key":"10365_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14041170","volume":"14","author":"DM Filippini","year":"2025","unstructured":"Filippini, D. M., et al. (2025). Vaccine-based immunotherapy for oropharyngeal and nasopharyngeal cancers. Journal of Clinical Medicine, 14, Article 1170.","journal-title":"Journal of Clinical Medicine"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10365-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10365-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10365-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:47:55Z","timestamp":1785822475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-026-10365-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["10365"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10365-8","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"54"}}